English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169283
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients

AuthorsGarcía, Juan L. ; Lozano, R.; Misiewicz-Krzeminska, Irena; Fernández-Mateos, Javier; Krzemiński, Patryk; Alfonso, S.; Marcos, R. A.; Gómez-Veiga, F.; Virseda, Á; Herrero, M.; Olmos, D.; Cruz, Juan Jesús
KeywordsAndrogen receptor
PTEN
CD133
Capillary nano-immunoassay
Circulating tumor cells
AR-V7
Issue Date2017
PublisherSpringer Nature
CitationClinical and Translational Oncology 19(11): 1350-1357 (2017)
Abstract[Purpose]: Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. [Methods]: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. [Results]: The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed: 37 cases showed ≥four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative. [Conclusions]: Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
Publisher version (URL)https://doi.org/10.1007/s12094-017-1675-5
URIhttp://hdl.handle.net/10261/169283
Identifiersdoi: 10.1007/s12094-017-1675-5
e-issn: 1699-3055
issn: 1699-048X
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
anovelpatient.pdf198,83 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.